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Abstract  
Background 
Biological sex can be an important source of variation in infection and immunity and sex-
dependent differences in immune response to vaccination have been reported in some studies.  
Methods 
We conducted an individual participant data meta-analysis of vaccine trials from one research 
centre, in which vaccines were administered to children under three years of age and 
immunological parameters measured. Log-transformed antigen-specific antibody and memory B 
cell results were meta-analysed and differences between girls and boys reported as geometric 
mean ratios. 
Results 
Antibody and memory B cell data were available from nine trials and 2378 children. Statistically 
significant differences between girls and boys were observed for diphtheria toxoid, capsular 
group A, W, and Y meningococcal, and pneumococcal vaccines. No sex-differences were 
observed for responses to Haemophilus influenzae type b, capsular group C meningococcal or 
tetanus toxoid vaccines.  
Conclusions 
In young children, immune responses to vaccines were consistently higher or equivalent in girls 
compared with boys. In no instance were responses in boys significantly higher than girls.  While 
these data do not indicate differences in protection conferred by immunisation in boys and girls, 
they do support further consideration of biological sex in planning of clinical trials of vaccines. 
3 
 
 
Keywords: antibody, memory B cells, sex-differences, infant, vaccine, individual participant 
data, meta-analysis
4 
 
Introduction  
There is increasing evidence that biological sex influences the immune response to vaccination 
and infection, however the biological mechanisms underpinning such differences are not well 
understood [1-3].  Elucidating the precise hormonal, genetic, behavioural and environmental 
mechanisms which are involved in sex-differential responses is a focus of ongoing research.  
In vaccinated adults, sex-differences in antibody response to vaccination have been observed to 
be greater for females after influenza [1], tetanus toxoid [4] and standard titre Schwarz measles 
vaccines [5] amongst others. Pneumococcal polysaccharide vaccine effectiveness has been 
reported to be greater in women than men [6] however other studies have shown pneumococcal 
antibody responses to be higher in men [7, 8]. Persistence of antibody after diphtheria toxoid 
vaccination has been observed to be higher in men in cross-sectional studies however such 
findings may be influenced by widespread vaccination of military recruits [9]. 
There are few published estimates of sex-specific immune responses for vaccines administered in 
infancy or early childhood.  Sex-specific estimates of immune responses to vaccination in 
children have been published in a small number of studies, which showed higher antibody titres 
to measles vaccine in female infants after vaccination with Edmonston-Zagreb measles vaccine 
but not after vaccination with Schwarz measles vaccine [10]. Additionally, higher anti-rubella 
titres have been reported in girls in studies of older children and adolescents [11, 12]. 
Women carry two X chromosomes which contain many genes involved in immune response 
mechanisms [13, 14], and sex-hormones are believed to influence protection [15]. Oestrogens 
promote proliferation of B cells and their maturation into plasma cells and are associated with 
inflammation, whereas androgens are associated with decreased antibody production and 
increased production of anti-inflammatory cytokines [1, 14]. 
5 
 
 
In only a minority of vaccine studies are immunological responses to vaccination in males and 
females reported separately. Although attempts have been made to review the available evidence 
of sex-biases [3, 6, 15], the non-publication of sex-specific trial results, particularly non-
significant findings, results in a form of publication bias which may distort conclusions drawn 
from systematic reviews. However, individual participant data from past vaccine studies can 
provide a source of information which is unaffected by publication bias. The aim of this meta-
analysis was to collate all data from available vaccine studies from one research centre to 
characterise sex-differences in vaccine-specific humoral and cellular immune responses.  
 
Methods:  
Data collection:  
Archives at a single study site in Oxford were surveyed to identify studies eligible for inclusion 
in the analysis.  Studies were eligible in which licensed or unlicensed vaccines were 
administered to children less than three years of age, and vaccine-specific responses were 
measured. 
 
Statistical analysis:  
Immunological data were log10-transformed and analysed using separate linear mixed effects 
models for each parameter at each time point. Sex, randomised group (where applicable), type of 
priming vaccine received at two to four months, and type of booster vaccine (for post-booster 
time points) were included in models as fixed effects. A random intercept for each study was 
included to allow for variation between studies [16]. The anti-log of the parameter estimate for 
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sex from the model was the estimate of interest presented herein as a geometric mean ratio 
(GMR) (female/male) with 95% confidence interval.  
In order to ensure all estimates of sex-differences were solely comparing vaccine-induced 
responses, participants were only included if the vaccine received (experimental or routine) 
contained the antigen for analysis. Control groups receiving no vaccine or an alternative vaccine 
which did not contain the antigen of analysis were therefore excluded.  
Due to the instability of models for binary data, particularly when the proportions of events are 
very high or very low, analyses of proportions were conducted as unadjusted two-stage random 
effects meta-analyses [17], with results presented as weighted risk differences.  
Analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). Two-stage 
meta-analyses of proportions were conducted using Stata version 13.0 (StataCorp, Texas, USA). 
 
Results 
Included studies 
There were nine studies and 2378 children with data available for inclusion in the meta-analysis, 
of which 47% were female (table 1). Information was available from six studies in which infants 
and children were randomised to receive different regimens of meningococcal vaccines [18-25], 
two studies in which pneumococcal vaccines were compared [26, 27], and one study which was 
designed to assess the effect of different needle sizes in the delivery of routine vaccinations [28]. 
Seven studies were solely conducted in the UK, one study was conducted in the UK and Malta 
[22, 23], and one study was conducted in Nepal [26]. Vaccines administered during the studies 
are detailed in supplementary table 1. All trials which contributed to each analysis are listed in 
supplementary tables 2 to 4. 
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The ratio of female to male infants in each study ranged from 0.69 to 1.03 with only one study 
having more females than males. For studies in which infants were enrolled at two months of age 
or younger, the ratio of female to male infants enrolled was 0.92, broadly reflecting the sex ratio 
at birth in the UK which is 0.95 [29] (table 2).  
 
Meningococcal vaccines 
Seven trials were available in which capsular group C meningococcal vaccines were 
administered in prime-boost combinations either as the study vaccine of interest or as a routine 
vaccine given concomitantly (trials #1 – 6, 8) [18-25, 28]. Immunological parameters 
(immunoglobulin (IgG), serum bactericidal assay (using rabbit or human complement) (rSBA, 
hSBA), and memory B cells) were measured post priming (at 5 months of age) and pre-and post-
boost (12 and 13 months of age). The ratio of responses in girls compared with boys was close to 
1.0 for most parameters and time points, and no significant sex-dependent differences were 
observed (figure 1, supplementary table 2). Geometric mean ratios ranged from 0.91 to 1.18. 
For capsular group A, W and Y meningococcal vaccines, two trials were available in which 
hSBA titres were measured (trials #3 and 4) [19, 24, 25]. Female/male response ratios ranged 
from 1.05 to 1.43 thus all point estimates favoured higher responses in girls. Significant 
differences were observed for responses to capsular groups A and Y at 5 months (1.33; 95% CI 
1.00 - 1.77 and 1.43; 1.02 - 2.00 respectively); W and Y at 12 months (1.34; 1.02 - 1.78 and 
1.43; 1.07 - 1.91 respectively); and capsular group A at 13 months of age (1.35; 1.00 - 1.83) 
(figure 1, supplementary table 2). 
Diphtheria toxoid vaccine 
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Seven trials were available in which IgG or memory B cell responses to diphtheria toxoid 
vaccination were measured (trials #1-3, 6-8) [18, 20-28]. Antibody responses to diphtheria 
toxoid were significantly higher in girls compared with boys at 12 months (pre-boost) (1.28; 1.05 
- 1.58) (figure 2, supplementary table 2). 
Tetanus toxoid and Haemophilus influenzae b vaccine 
IgG or memory B cells responses to tetanus toxoid vaccination were available from six trials 
(#2,3,5-8) [18, 21-25, 27, 28]and responses to Haemophilus influenzae type b (Hib) vaccination 
in four trials (#3,5,6,8) [21-25, 28]. There were no significant differences between girls and boys 
for these antigens at any time point (figure 2, supplementary table 2).  
Pneumococcal conjugate vaccines 
Serotype-specific pneumococcal antibody concentrations were measured in three studies 
administering 10- or 13-valent pneumococcal conjugate vaccine as either the study vaccine or as 
a routine vaccine given concomitantly (#6,7,9) [22, 23, 26, 27]. Opsonophagocytic activity 
(OPA) was measured in two of these studies (#7,9). Response to vaccination was assessed one 
month following the priming series (at ~4-5 months of age) and at one month post booster 
vaccination (at ~10-13 months of age). Antibody persistence was measured pre-booster (at 9 or 
12 months of age) and one year following the booster (at 24 months of age). Antibody 
persistence was greater in girls compared with boys for all serotypes, with statistically significant 
differences observed for eight serotypes prior to boosting and nine serotypes at one year 
following the booster. Significant differences were also observed for five serotypes at one month 
after the priming series. The antibody response to only one serotype (6B) was significantly 
higher in girls compared with boys one month post-booster (figure 3, supplementary table 3).  
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Fewer data were available for assessment of OPA thus confidence intervals for estimates were 
wide, however a similar consistent pattern of point estimates which were mostly higher in girls 
was observed (supplementary table 4, supplementary figure 1). 
An analysis of the proportions of children with serotype-specific IgG ≥ 0.35 μg/mL showed that 
the persistence against serotypes 1, 6B, 19F and 23F was greater for females at 10-12 months 
(pre-boost), with differences of between 6% to 15%. Antibody persistence against serotype 18C 
was also significantly higher in females at one-year post booster (supplementary table 5). With 
the exception of serotypes 6B and 23F, proportions of children with IgG ≥ 0.35 μg/mL at one 
month after vaccination (either prime or boost) were consistently high and therefore differences 
in proportions were undetectable. 
 
Discussion: 
Biological sex has a pervasive influence on immune responses as documented by a large body of 
literature on infections and autoimmune diseases.  The incidence of almost all autoimmune 
diseases is higher in women [30], with, for example, incidence rates of hyperthyroidism and 
multiple sclerosis approximately twice as high as for men [30, 31]. Conversely, higher rates of 
some childhood infections occur in males: for example, incidence of both bacterial and viral 
meningitis in children is higher in males than females [31, 32]. Furthermore, bacterial meningitis 
and septicaemia rates (especially Gram negative infection) were higher in male than in female 
newborns,[33] children,[34] and in boys under five years of age [35, 36]. A meta-analysis of 
serogroup-specific pneumococcal disease cases revealed that pneumococcal isolates were 1.8 
times more frequently found in males across all serogroups [37]. 
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To the extent that biological sex is not practically modifiable in the context of immunisation 
programs its contribution to variation in immune response has been relatively neglected. 
However, sex biases can reveal important insights into mechanisms of immunogenicity and have 
practical implications for vaccine licensing, efficacy and related adverse events. Previous 
literature reviews on vaccine responses have mainly summarised data from adults or older-
children rather than infants receiving a primary course of immunisation and reveal a general 
pattern of higher humoral responses in females [3, 5, 38, 39]. Our analysis is the first individual 
participant data meta-analysis of infant vaccine studies undertaken with the specific aim of 
investigating whether vaccine immunogenicity is affected by biological sex. Overall, for all 
vaccines and all measures of immunogenicity, female responses were either higher than or 
equivalent to males and there were no instances where male responses were significantly higher 
than those in females.  
 
The clinical relevance of such differences in immune response is unclear. Important factors to 
consider in the current analyses are i) the magnitude of the difference, ii) the relationship 
between immune response and correlates of protection, iii) the importance of herd immunity in 
addition to direct protection and iv) that the immune responses as measured by B-cell assays may 
only be surrogates of more important T-cell responses or responses at mucosal surfaces where 
infection occurs. 
 
For most outcomes, responses were higher in females than in males. The largest differences were 
seen in pneumococcal serotype-specific OPA where 2- to 3- fold higher responses in girls were 
observed for some serotypes. Such differences could be considered clinically relevant; however, 
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greater responses to vaccination in female infants do not necessarily imply increased direct 
protection if responses for both sexes are higher than the required thresholds for protection 
against disease. For some vaccine-induced responses, thresholds have been determined whereby 
assay values above the threshold are generally thought to provide protection against disease [40, 
41] Our analysis of pneumococcal antibodies revealed that there were some significant 
differences in GMRs that did translate into significant differences in the proportions with IgG ≥ 
0.35 μg/mL. This provides some insight into differences between the sexes in the proportions 
with assumed protection against disease however immune correlates of protection tend to vary 
by serotype and assay, and for some assays there are no agreed thresholds [42]. 
With the exception of tetanus, all vaccines included in this analysis rely, to some extent, on herd 
protection rather than direct protection to guard against disease and thus male infants (and the 
unvaccinated population in general) still benefit from higher humoral responses in females. The 
relative differences reported here, for a mostly UK population, will have different clinical 
relevance when applied to other countries. 
 
There is a strong biological basis for sex-based differences in the immune system in response to 
pathogen exposure, infection and vaccination [14, 15, 43]. In general biological sex is 
determined by the presence or absence of the Y-chromosome whose expression of the sry gene 
in early foetal development results in the formation of testes rather than the default program 
which is to produce ovaries. The mechanisms underlying any effect of sexual dimorphism are 
complex and may arise from i) Y-chromosome genes other than sry (around 200 genes are 
present), ii) the radically different hormonal environment of the male versus the female from 
foetal life through infancy and beyond, iii) behavioural and environmental differences between 
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the sexes which may stem from genetic, hormonal or social factors and iv) the potential 
advantage of a diploid versus haploid state for the X-chromosome in females. Mediators of these 
differences may operate through a large variety of pathways and on different time scales. For 
instance the influence of the genetic and hormonal environment in utero may leave epigenetic 
differences on autosomal chromosomes that have effects at more remote time-points 
postnatally[44]. 
One of the most well-established mechanisms for differences in immunity is the sex-hormone 
milieu. Oestrogen and androgen receptors are present in a wide-range of immune cells and the 
immunosuppressive nature of androgens are established [14, 15]. Due to a variable distribution 
of oestrogen receptor subtypes on the immune cells and the exposure to different concentrations 
of oestrogens, the effect of oestrogen on different aspects of immune function can be variable 
whereas the effect of progesterone on immune function is thought to be mainly suppressive [3]. 
The concentrations of both hormones increases during pregnancy with an associated shift 
towards a more T helper cell type 2 (Th2) phenotype by the third trimester and an associated 
increased susceptibility to viral infections including influenza and varicella.  
 
Previous work has found that immune responses following vaccination are different between the 
sexes. Following yellow fever vaccination, the number of differentially expressed genes of the 
innate immune system was much greater in women than men with notable differences in 
induction of Toll-like receptor-interferon signalling [3]. Sex-dependent differences in the 
immune response to vaccination might also result from differences in expression of immune 
genes located on the X chromosome, and are associated with certain X-linked primary 
immunodeficiencies. Toll-like receptors (TLR) 7 and 8 are both located on the X chromosome 
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and recognise viral single-stranded RNA. Although it is unknown whether these genes have an 
effect on the responses to vaccines, it is possible that differential expression of TLR 7/8 through 
failure of X inactivation may enhance antiviral responses [45]. 
 
Whilst there appear to be a variety of mechanisms, there are clearly vaccine antigens for which 
there are no sex-differences. We observed no sex-differences in response to tetanus vaccines nor 
in response to Hib vaccines (which are often conjugated to a tetanus toxoid). The majority of 
meningococcal and pneumococcal vaccines administered in these studies were conjugated to a 
mutant diphtheria cross-reacting material (CRM197). The consistent pattern for greater responses 
in females seen following immunisation with meningococcal, pneumococcal and diphtheria 
vaccines, but not seen for tetanus and Hib, may suggest a sex-differential effect of the carrier 
protein. There exists a complicated interplay of effects of different carrier proteins for different 
antigens in crowded immunisation schedules administering multiple vaccines in combination 
[46].  
 
The findings in this report have important implications for future randomised trials. It is 
important that trials of new vaccines are designed to compare immune responses according to 
sex, and in situations where vaccine responses have been convincingly shown to be higher in 
females, demonstrate that sufficient protection is provided in males independently.  
 
There are limitations to the analyses detailed herein. Trials combined in these analyses tested 
different vaccines and there were variations in trial procedures. Although trials included in these 
analyses were designed to answer different questions and comparisons between trials would not 
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be valid, comparisons between sexes within trials can be combined in an unbiased manner. 
Heterogeneity between trials is more likely to introduce ‘noise’ into calculations and obscure 
detection of true differences rather than induce bias. 
 
Multiple comparisons are an issue in meta-analyses as type 1 error rates become inflated and 
false positive findings can result. However, the findings of this analysis when viewed in their 
entirety, are generally consistent in direction and magnitude and point to underlying biological 
effects which result in higher immunological responses in females. Although this is the first 
meta-analysis designed to assess sex-differences in vaccine-specific responses, limited data were 
available for some vaccine antigens. This results in low statistical power and wide confidence 
intervals for some comparisons therefore meta-analyses of larger numbers of studies are still 
needed.  
 
Reporting bias is an important consideration in this field as characterising differences between 
female and male responses is not usually an aim of any vaccine trial and the post-hoc 
investigation of subgroup differences is not good practice due to the lack of statistical power. 
Thus sex-differential results are either not assessed in most trials or not generally reported which, 
although appropriate, hampers the relevance of literature-based reviews. Although our policy is 
to publish all results from clinical trials, the publication of analyses according to subgroups 
which were not the original intent of the study is not undertaken. Here, we have systematically 
analysed individual participant data from all our available studies and publish results of 
significant and non-significant analyses concurrently.  
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While the possibilities of “personalised vaccination” [47] are currently remote, a detailed 
understanding of the influence of biological sex on immunogenicity could potentially allow the 
utilisation of these effects in order to optimise protection through routine immunisations. 
However, only with sufficient high-quality evidence will it be feasible to fully evaluate whether 
further improvements can be made to current routine infant vaccination schedules, which have 
well-established and significant public health benefits [48], preventing an estimated 2 million 
child deaths every year [49].  
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Table 1: Details of included studies 
Study 
number   
Full study title Sponsor Ref 
1 A Phase II Randomised Comparison to Determine the Safety and Immunogenicity of a Conjugate 
Vaccine Combination containing Meningococcal Group C & Pneumococcal capsular Polysaccharide – 
CRM197 conjugate, given concurrently with DTP/Hib in healthy infants (D139-P502) 
Chiron S.r.l. 
Via Fiorentina, 1 
53100 Siena, Italy 
[20] 
2 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C 
Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine (Menjugate) Administered to 
Healthy Children at least 12 months of Age After Priming with Menjugate at 2, 3 and 4 Months of age. 
(2004-004962-33) 
Chiron S.r.l. 
Via Fiorentina, 1 
53100 Siena, Italy 
[18] 
3 A Phase II, Randomized, Open label, Controlled, Multicenter Study to Evaluate the Safety, 
Immunogenicity and Induction of Immunological Memory after Two or Three Doses of Chiron 
Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants at 2, 3, 4 or 2, 4, 6 Months of 
Age (NCT00262002) 
Chiron S.r.l. 
Via Fiorentina, 1 
53100 Siena, Italy 
[24, 
25] 
4 A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, 
W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis 
Meningococcal ACWY Conjugate Vaccine in Healthy Infants (NCT00488683) 
Novartis Vaccines 
and Diagnostics Srl 
Via Fiorentina, 1 
53100 Siena, Italy 
[19] 
5 Double blind, randomised controlled trial of the immunogenicity and tolerability of a meningococcal group 
C conjugate vaccine (D110-500) 
Wyeth – Lederle 
Vaccines 
[21] 
6 An open label randomised controlled study to evaluate the induction of immune memory following infant 
vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the immune 
response to the concurrent infant routine immunisations administered in consistent versus alternating 
limbs (2009-016579-31) 
University of Oxford [22, 
23] 
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7 A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent 
pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate 
vaccine booster given at 12 months of age to healthy children who have received the 13-valent 
pneumococcal conjugate vaccine at 2 and 4 months of age. (NCT01443416) 
University of Oxford [27] 
8 Effect of needle size on serum antibody responses and incidence of local reactions following routine 
immunisation in infants - a randomised controlled trial. 
University of Oxford [28] 
9 A randomised open-label immunogenicity study of a 10 Valent Pneumococcal vaccine.  
(PCV10) given as part of the routine infant immunisation schedule to children in 
Kathmandu, Nepal. (ISRCTN56766232) 
University of Oxford [26] 
 
Table 2: Details of infants included the analysis 
Study 
number   
Year enrolment 
commenced 
Number girls/ number 
boys (ratio) 
Age at 
enrolment 
Ages at vaccination 
1 2000 51/74 (0.69) 12 months 12 months 
2 2005 16/17 (0.94) 2 months 2,3,4 months 
3 2004 157/152 (1.03) 2 months 2,3,4 months 
4 2007 95/109 (0.87) 2 months 2,3,4 months 
5 1997 108/123 (0.88) 2 months 2,3,4 months 
6 2010 210/229 (0.92) 2 months 2,3,4 + 12 months 
7 2012 50/75 (0.67) 12 months 12 months 
8 2002 336/360 (0.93) 2 months 2,3,4 months 
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9 2010 98/118 (0.83) 6 weeks 6,14 weeks + 9 months, or 6,10,14 weeks 
TOTAL  1121/1257 (0.89)   
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Figure Legends 
Figure 1 Female-male geometric mean ratios (95% CI) of serotype-specific 
immunogenicity from meta-analyses of meningococcal vaccines in infants. 
 
Each point estimate represents the summary GMR from one meta-analysis. Lines indicate 
95% confidence intervals. A GMR of 1.0 represents no difference in responses between 
females and males. 5 months = one-month post-prime, 12 months = pre-boost, 13 
months=one-month post-boost, 24 months = persistence at one year post-boost. 
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hSBA: serum bactericidal assay (human complement), rSBA: serum bactericidal assay (rabbit 
complement), IgG: immunoglobulins, GMR: geometric mean ratio (female/male) 
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Figure 2 Female-male geometric mean ratios (95% CI) of serotype-specific 
immunogenicity from meta-analyses of diphtheria toxoid, tetanus toxoid and 
Haemophilus influenzae type B  vaccine-induced responses in infants. 
Each point estimate represents the summary GMR from one meta-analysis. Lines indicate 
95% confidence intervals. A GMR of 1.0 represents no difference in responses between 
females and males. 5 months = one-month post-prime, 12 months = pre-boost, 13 months= 
one-month post-boost, 24 months = persistence at one year post-boost. 
PRP: Polyribosylribitol phosphate, IgG: immunoglobulins, GMR: geometric mean ratio 
(female/male) 
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Figure 3 Female-male geometric mean ratios (95% CI) of serotype-specific 
immunoglobulins from meta-analyses of pneumococcal vaccines in infants. 
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Each point estimate represents the summary GMR from one meta-analysis. Lines indicate 
95% confidence intervals. A GMR of 1.0 represents no difference in responses between 
females and males. 5 months = one-month post-prime, 12 months = pre-boost, 13 months = 
one-month post-boost, 24 months = persistence at one year post-boost. 
IgG: immunoglobulins, GMR: geometric mean ratio (female/male) 
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